Quantitative data concerning tumor-to-contralateral site ratios for primary tumors with different HER2 expression levels and for HER2-positive lymph node lesions, where the number of lesions is sufficient for statistical treatment, are shown in Tables 5 and 6. This evidence concerns the gene ERBB2 and neoplasm.